市場調查報告書
商品編碼
1402484
歐洲左心室輔助裝置市場預測至 2028 年 - 區域分析 - 依流程類型、設計與應用Europe Left Ventricular Assist Device Market Forecast to 2028 - Regional Analysis - by Type of Flow, Design, and Application |
歐洲左心室輔助裝置市場預計將從2022年的3.3652億美元成長到2028年的4.4505億美元。預計2022年至2028年CAGR為4.8%。
LVAD 中人工智慧和機器學習的使用增加推動歐洲左心室輔助設備市場
與 LVAD 相關的併發症和不良事件發生率的增加鼓勵製造商開發創新技術並將新技術整合到設備中。在某些情況下,使用 LVAD 裝置的患者會出現右心室衰竭,導致靜脈積血和腫脹。為了減少故障,製造商整合了人工智慧 (AI),透過 LVAD 監測右心室。因此,右心室活動和功能的任何變化都將報告給醫療保健專業人員,從而減少右心室衰竭和併發症的機會。
此外,擴大使用機器學習(ML)來制定心臟衰竭死亡率的風險評分,這比傳統方法具有優勢。此外,穿戴式裝置的遙測資料分析有助於預測心臟衰竭住院。機器學習演算法用於獲取 2D 和 3D 超音波心動圖上的三尖瓣環偏移,這有助於評估右心室功能。此外,基於機器學習的演算法使用 3D 超音波心動圖影像來研究右心室容積和射血分數,提供準確的資料和高效的心臟功能自動分析。
因此,利用人工智慧和機器學習演算法有助於開發基於左心室輔助功能的末期心臟衰竭患者右心室功能的風險預測模型。右心室衰竭的風險分層是幫助確定患者存活的重要因素之一。因此,在預測期內,在 LVAD 中使用人工智慧和機器學習很可能成為左心室輔助裝置 (LVAD) 市場的主要趨勢。
歐洲左心室輔助裝置市場概況
英國國會的資料顯示,2019年英國總人口中約有五分之一年齡在65歲及以上。而且,2009年至2019年間,該年齡層人口數量增加了23%,而英國總人口則增加了同期僅7%。 65歲或以上的人是心血管疾病和心臟衰竭的高發生率。隨著心臟衰竭盛行率的增加,英國心臟移植的等待名單很長。根據英國心臟基金會的研究,2019年英國約有300人患有LVAD,而2012年只有約100人患有LVAD。根據英國老年醫學會提供的資料,2020年,~英國有100 萬人患有心臟衰竭,約5% 因緊急情況入院的人患有心臟衰竭。 2020 年,國家醫療服務 (NHS) 總支出的約 2% 用於心臟衰竭的治療。心臟衰竭盛行率的激增正在推動英國 LVAD 市場的成長。
歐洲左心室輔助裝置市場收入及 2028 年預測(百萬美元)
歐洲左心室輔助裝置市場細分
歐洲左心室輔助裝置市場按流程類型、設計、應用和國家進行細分。
根據血流類型,歐洲左心室輔助裝置市場分為脈動血流和非脈動血流。 2022年,非脈動血流細分市場在歐洲左心室輔助裝置市場中佔有更大佔有率。
根據設計,歐洲左心室輔助裝置市場分為植入式心室輔助裝置和經皮心室輔助裝置。 2022年,植入式心室輔助裝置細分市場在歐洲左心室輔助裝置市場中佔有更大佔有率。
根據應用,歐洲左心室輔助裝置市場分為移植橋樑、目的地治療、恢復橋樑和候選橋樑。 2022年,目的地治療細分市場在歐洲左心室輔助裝置市場中佔最大佔有率。
根據國家/地區,歐洲左心室輔助裝置市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2022年,英國在歐洲左心室輔助裝置市場中佔最大佔有率。
Abbott Laboratories、Medtronic Plc、Evaheart Inc. 和 CorWave SA 是歐洲左心室輔助裝置市場上的一些領先公司。
The Europe left ventricular assist device market is expected to grow from US$ 336.52 million in 2022 to US$ 445.05 million by 2028. It is estimated to grow at a CAGR of 4.8% from 2022 to 2028.
Increased Use of Artificial Intelligence and Machine Learning in LVAD Drive Europe Left Ventricular Assist Device Market
The increased incidence of complications and adverse events associated with LVAD encouraged manufacturers to develop innovative technologies and integrate new technologies into the devices. In several cases, patients with LVAD devices experience right ventricle failure leading to blood buildup in veins and swelling. To reduce the failure, manufacturers have integrated artificial intelligence (AI) to monitor the right ventricle with LVAD. Therefore, any change in the right ventricle activity and function will be reported to the healthcare professional, reducing the chances of right ventricle failure and complications.
Furthermore, the increased use of machine learning (ML) for developing risk scores for heart failure mortality provides an edge over conventional methods. Additionally, telemetry data analysis from wearable devices helps predict heart failure hospitalizations. Machine learning algorithms are used to access tricuspid annulus excursion on 2D and 3D echocardiography, which helps in the assessment of right ventricle function. Moreover, machine learning-based algorithms use 3D echocardiographic images to study the right ventricle volume and ejection fraction, providing exact data and efficient automated analysis of heart function.
Therefore, the use of artificial intelligence and machine learning algorithms helps develop a risk prediction model based on right ventricle functions in end-stage heart failure patients with LVAD. The risk stratification for right ventricle failure is one of the significant factors that help determine the patients' survival. Therefore, the use of artificial intelligence and machine learning in LVAD is likely to emerge as a key trend in the left ventricle assist devices (LVAD) market during the forecast period.
Europe Left Ventricular Assist Device Market Overview
According to the UK Parliament's data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Moreover, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. People aged 65 or above are highly prone to cardiovascular diseases and heart failure. With the increasing prevalence of heart failure, the waiting list for heart transplantation is long in the UK. According to a study by the British Heart Foundation, ~300 people were living with LVAD in the UK in 2019, while only ~100 people were living with LVAD in 2012. According to the data provided by the British Geriatrics Society, in 2020, ~1 million people in the UK were living with heart failure, and ~5% of the people admitted to hospitals for emergencies were suffering from heart failure. In 2020, ~2% of the total National Health Service (NHS) expenditure is spent on treatment of heart failure. A surge in the prevalence of heart failure is propelling the growth of the LVAD market in the UK.
Europe Left Ventricular Assist Device Market Revenue and Forecast to 2028 (US$ Million)
Europe Left Ventricular Assist Device Market Segmentation
The Europe left ventricular assist device market is segmented into type of flow, design, application, and country.
Based on type of flow, the Europe left ventricular assist device market is bifurcated into pulsatile flow and non-pulsatile flow. In 2022, the non-pulsatile flow segment registered a larger share in the Europe left ventricular assist device market.
Based on design, the Europe left ventricular assist device market is bifurcated into implantable ventricular assist devices and transcutaneous ventricular assist devices. In 2022, the implantable ventricular assist devices segment registered a larger share in the Europe left ventricular assist device market.
Based on application, the Europe left ventricular assist device market is segmented into Bridge to transplantation, destination therapy, bridge to recovery, and bridge to candidacy. In 2022, the destination therapy segment registered the largest share in the Europe left ventricular assist device market.
Based on country, the Europe left ventricular assist device market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe left ventricular assist device market.
Abbott Laboratories, Medtronic Plc, Evaheart Inc., and CorWave SA are some of the leading companies operating in the Europe left ventricular assist device market.